{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:44:29Z","timestamp":1781808269981,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Basic Research Project of Zhejiang Provincial Department of Science and Technology","award":["2018C37132"],"award-info":[{"award-number":["2018C37132"]}]},{"name":"The Key Provincial Ministry Joint Construction Program of Zhejiang Provincial Health Commission","award":["WKJ-ZJ-1809"],"award-info":[{"award-number":["WKJ-ZJ-1809"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s13760-021-01843-7","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:24:46Z","timestamp":1638210286000},"page":"1557-1566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson\u2019s disease in Chinese patients"],"prefix":"10.1007","volume":"122","author":[{"given":"Qi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejia","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8590-0926","authenticated-orcid":false,"given":"Song","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"issue":"8","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124(8):901\u2013905","journal-title":"J Neural Transm (Vienna)"},{"key":"1843_CR2","doi-asserted-by":"crossref","unstructured":"Stoker TB, Barker RA (2020) Recent developments in the treatment of Parkinson\u2019s disease. F1000Res 9(Faculty Rev):862","DOI":"10.12688\/f1000research.25634.1"},{"issue":"1\u20132","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.04.005","volume":"306","author":"LF Burbulla","year":"2011","unstructured":"Burbulla LF, Kruger R (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson\u2019s disease. J Neurol Sci 306(1\u20132):1\u20138","journal-title":"J Neurol Sci"},{"issue":"30","key":"1843_CR4","doi-asserted-by":"publisher","first-page":"24862","DOI":"10.1074\/jbc.M112.348128","volume":"287","author":"KS Kim","year":"2012","unstructured":"Kim KS et al (2012) Proteolytic cleavage of extracellular alpha-synuclein by plasmin: implications for Parkinson disease. J Biol Chem 287(30):24862\u201324872","journal-title":"J Biol Chem"},{"issue":"2","key":"1843_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4161\/pri.22850","volume":"7","author":"SM Park","year":"2013","unstructured":"Park SM, Kim KS (2013) Proteolytic clearance of extracellular alpha-synuclein as a new therapeutic approach against Parkinson disease. Prion 7(2):121\u2013126","journal-title":"Prion"},{"issue":"5","key":"1843_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40520-015-0504-3","volume":"28","author":"M Gorska-Ciebiada","year":"2016","unstructured":"Gorska-Ciebiada M et al (2016) Plasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptoms. Aging Clin Exp Res 28(5):843\u2013851","journal-title":"Aging Clin Exp Res"},{"issue":"4","key":"1843_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1160\/TH05-01-0033","volume":"93","author":"C Dellas","year":"2005","unstructured":"Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93(4):631\u2013640","journal-title":"Thromb Haemost"},{"issue":"4","key":"1843_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.thromres.2009.02.014","volume":"124","author":"R Palmirotta","year":"2009","unstructured":"Palmirotta R et al (2009) Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 124(4):403\u2013408","journal-title":"Thromb Res"},{"issue":"1\u20132","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0006-8993(99)01645-5","volume":"837","author":"MY Ahn","year":"1999","unstructured":"Ahn MY et al (1999) Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res 837(1\u20132):169\u2013176","journal-title":"Brain Res"},{"issue":"6","key":"1843_CR10","first-page":"5517","volume":"15","author":"H Pan","year":"2018","unstructured":"Pan H et al (2018) Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson\u2019s disease. Exp Ther Med 15(6):5517\u20135522","journal-title":"Exp Ther Med"},{"key":"1843_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109602","volume":"138","author":"CJ Reuland","year":"2020","unstructured":"Reuland CJ, Church FC (2020) Synergy between plasminogen activator inhibitor-1, alpha-synuclein, and neuroinflammation in Parkinson\u2019s disease. Med Hypotheses 138:109602","journal-title":"Med Hypotheses"},{"issue":"2","key":"1843_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1024\/0301-1526\/a000839","volume":"49","author":"Q Zhang","year":"2020","unstructured":"Zhang Q et al (2020) Plasminogen activator inhibitor-1 (PAI-1) 4G\/5G promoter polymorphisms and risk of venous thromboembolism\u2014a meta-analysis and systematic review. Vasa 49(2):141\u2013146","journal-title":"Vasa"},{"issue":"4","key":"1843_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12031-014-0418-0","volume":"54","author":"X Huang","year":"2014","unstructured":"Huang X et al (2014) Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women. J Mol Neurosci 54(4):803\u2013810","journal-title":"J Mol Neurosci"},{"issue":"1","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cardiores.2004.03.023","volume":"63","author":"C Roncal","year":"2004","unstructured":"Roncal C et al (2004) Influence of the 4G\/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 63(1):176\u2013185","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1843_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.parkreldis.2014.04.019","volume":"20","author":"J Joutsa","year":"2014","unstructured":"Joutsa J et al (2014) Diagnostic accuracy of Parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 20(8):840\u2013844","journal-title":"Parkinsonism Relat Disord"},{"key":"1843_CR16","doi-asserted-by":"crossref","first-page":"1539096","DOI":"10.1155\/2016\/1539096","volume":"2016","author":"S Pelletier","year":"2016","unstructured":"Pelletier S et al (2016) Investigation of cognitive improvement in alcohol-dependent inpatients using the Montreal Cognitive Assessment (MoCA) score. J Addict 2016:1539096","journal-title":"J Addict"},{"issue":"3","key":"1843_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1566523218666180430121323","volume":"18","author":"R Titze-de-Almeida","year":"2018","unstructured":"Titze-de-Almeida R, Titze-de-Almeida SS (2018) miR-7 replacement therapy in Parkinson\u2019s disease. Curr Gene Ther 18(3):143\u2013153","journal-title":"Curr Gene Ther"},{"issue":"19","key":"1843_CR18","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.3390\/ijms21197066","volume":"21","author":"FA Rahman","year":"2020","unstructured":"Rahman FA, Krause MP (2020) PAI-1, the plasminogen system, and skeletal muscle. Int J Mol Sci 21(19):7066","journal-title":"Int J Mol Sci"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajp.2019.05.021","volume":"43","author":"S Elmi","year":"2019","unstructured":"Elmi S et al (2019) Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis. Asian J Psychiatr 43:105\u2013110","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"1843_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1160\/TH08-07-0427","volume":"100","author":"RD Balsara","year":"2008","unstructured":"Balsara RD, Ploplis VA (2008) Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 100(6):1029\u20131036","journal-title":"Thromb Haemost"},{"issue":"8","key":"1843_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/biom9080341","volume":"9","author":"R Samarakoon","year":"2019","unstructured":"Samarakoon R et al (2019) The TGF-beta1\/p53\/PAI-1 signaling axis in vascular senescence: role of caveolin-1. Biomolecules 9(8):341","journal-title":"Biomolecules"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.2741\/2285","volume":"12","author":"Y Aso","year":"2007","unstructured":"Aso Y (2007) Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12:2957\u20132966","journal-title":"Front Biosci"},{"issue":"3","key":"1843_CR23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s11064-016-2088-5","volume":"42","author":"AR Jayakumar","year":"2017","unstructured":"Jayakumar AR, Apeksha A, Norenberg MD (2017) Role of matricellular proteins in disorders of the central nervous system. Neurochem Res 42(3):858\u2013875","journal-title":"Neurochem Res"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fnins.2020.00863","volume":"14","author":"MT Flores-Dorantes","year":"2020","unstructured":"Flores-Dorantes MT, Diaz-Lopez YE, Gutierrez-Aguilar R (2020) Environment and gene association with obesity and their impact on neurodegenerative and neurodevelopmental diseases. Front Neurosci 14:863","journal-title":"Front Neurosci"},{"issue":"12","key":"1843_CR25","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.euroneuro.2014.03.002","volume":"24","author":"IA Arnoldussen","year":"2014","unstructured":"Arnoldussen IA, Kiliaan AJ, Gustafson DR (2014) Obesity and dementia: adipokines interact with the brain. Eur Neuropsychopharmacol 24(12):1982\u20131999","journal-title":"Eur Neuropsychopharmacol"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.gene.2018.06.040","volume":"673","author":"Y Liu","year":"2018","unstructured":"Liu Y et al (2018) The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects. Gene 673:167\u2013173","journal-title":"Gene"},{"issue":"1","key":"1843_CR27","first-page":"52","volume":"118","author":"D Alexa","year":"2014","unstructured":"Alexa D et al (2014) Parkinson\u2019s disease and carotid intima-media thickness. Rev Med Chir Soc Med Nat Iasi 118(1):52\u201356","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"10","key":"1843_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/FPC.0b013e328308bbc0","volume":"18","author":"SJ Tsai","year":"2008","unstructured":"Tsai SJ et al (2008) Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genom 18(10):869\u2013875","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"1843_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/jcpt.12470","volume":"42","author":"C Yenilmez","year":"2017","unstructured":"Yenilmez C et al (2017) A study of the possible association of plasminogen activator inhibitor type 1 4G\/5G insertion\/deletion polymorphism with susceptibility to schizophrenia and in its subtypes. J Clin Pharm Ther 42(1):103\u2013107","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"1843_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535","journal-title":"Lancet Neurol"},{"issue":"9","key":"1843_CR31","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/WNL.38.9.1402","volume":"38","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson\u2019s disease. Neurology 38(9):1402\u20131406","journal-title":"Neurology"},{"issue":"4","key":"1843_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","volume":"5","author":"A Schrag","year":"2006","unstructured":"Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset Parkinsonism. Lancet Neurol 5(4):355\u2013363","journal-title":"Lancet Neurol"},{"issue":"4","key":"1843_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1134\/S0026893320040123","volume":"54","author":"GJ Osmak","year":"2020","unstructured":"Osmak GJ et al (2020) Age-dependent approach to search for genetic variants associated with myocardial infarction. Mol Biol (Mosk) 54(4):699\u2013704","journal-title":"Mol Biol (Mosk)"},{"issue":"8","key":"1843_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","volume":"11","author":"P Svenningsson","year":"2012","unstructured":"Svenningsson P et al (2012) Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11(8):697\u2013707","journal-title":"Lancet Neurol"},{"issue":"2","key":"1843_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3233\/JAD-171038","volume":"63","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) Association between plasma levels of PAI-1, tPA\/PAI-1 molar ratio, and mild cognitive impairment in Chinese patients with type 2 diabetes mellitus. J Alzheimers Dis 63(2):835\u2013845","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1843_CR36","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3892\/etm.2016.3162","volume":"11","author":"X Li","year":"2016","unstructured":"Li X et al (2016) Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment. Exp Ther Med 11(5):1993\u20131998","journal-title":"Exp Ther Med"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-021-01843-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T17:34:53Z","timestamp":1673890493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-021-01843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s13760-021-01843-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed and performed in agreement with the Declaration of Helsinki and was approved by Medical Ethics Committee of Zhejiang Hospital (Approval number: 2018(14K)). Written informed consent was obtained from individual or guardian participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}